SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vineet Laboratories - Quaterly Results

09 Nov 2025 Evaluate
The sales is pegged at Rs. 174.20 millions for the September 2025 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 189.58 millions during the year-ago period.The Total Profit for the quarter ended September 2025 of Rs. 4.00 millions grew from Rs.-18.28 millions Operating profit Margin for the quarter ended September 2025 improved to 31.83% as compared to -1.06% of corresponding quarter ended September 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 174.20 189.58 -8.11 248.62 428.20 -41.94 749.95 1505.91 -50.20
Other Income 0.08 2.00 -96.00 0.26 5.73 -95.46 19.87 4.63 329.16
PBIDT 31.83 -1.06 -3102.83 35.19 -5.29 -765.22 -142.96 76.63 -286.56
Interest 21.87 9.90 120.91 27.99 21.27 31.59 39.78 47.81 -16.80
PBDT 9.96 -10.96 -190.88 7.20 -26.56 -127.11 -182.74 28.82 -734.07
Depreciation 6.25 6.16 1.46 12.50 12.25 2.04 25.02 25.19 -0.67
PBT 3.71 -17.12 -121.67 -5.30 -38.81 -86.34 -207.76 3.63 -5823.42
TAX -0.29 1.16 -125.00 -0.65 0.79 -182.28 -5.85 -6.64 -11.90
Deferred Tax -0.29 1.16 -125.00 -0.65 0.79 -182.28 -5.85 -5.99 -2.34
PAT 4.00 -18.28 -121.88 -4.65 -39.60 -88.26 -201.91 10.27 -2066.02
Equity 92.19 92.19 0.00 92.19 92.19 0.00 92.19 92.19 0.00
PBIDTM(%) 18.27 -0.56 -3368.13 14.15 -1.24 -1245.71 -19.06 5.09 -474.61

Vineet Laboratories Share Price

32.75 -0.36 (-1.09%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×